Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537471 | 0.81 | SLC13A5 (0.37) | NR3C2NR3C1 | |
| SCHEMBL3536776 | 0.81 | ATM (0.42) | NR3C2NR3C1 | |
| SCHEMBL3535437 | 0.76 | AKR1C3 (0.36) | — | |
| SCHEMBL3536325 | 0.75 | CTSS (0.38) | NR3C2NR3C1 | |
| SCHEMBL3530604 | 0.74 | CTSS (0.36) | — | |
| SCHEMBL1775018 | 0.73 | NR3C1 (0.67) | NR3C2NR3C1 | |
| SCHEMBL1775343 | 0.73 | NR3C1 (0.67) | NR3C2NR3C1 | |
| SCHEMBL1775956 | 0.73 | NR3C1 (0.67) | NR3C2NR3C1 | |
| SCHEMBL31445827 | 0.72 | NR3C2 (0.49) | NR3C2NR3C1 | |
| SCHEMBL17420552 | 0.72 | NR3C2 (0.49) | NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| EP-2013185-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| WO-2007122165-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265326-A1 | NOVEL COMPOUNDS | CCL11, MRGPRX2, LTB4R2 | NR3C2 271/4885NR3C1 190/4885 |
| US-20090111866-A1 | Novel Compounds | CCL11, MRGPRX2, LTB4R2 | NR3C2 271/4885NR3C1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.